Gilead Sciences has completed its acquisition of Tubulis, a Munich, Germany-based clinical-stage bio/pharmaceutical company developing antibody-drug conjugates (ADCs), in a deal worth up to $5 billion ($3.15 billion upfront and $1.85 billion in milestone payments).  

The acquisition expands Gilead’s ADC capabilities by adding assets and platforms designed to deliver diverse payloads to solid tumors. Tubulis’ lead asset, TUB-040, is currently in Phase Ib/II development for treating platinum-resistant ovarian cancer and non-small cell lung cancer. It is a NaPi2b-directed topoisomerase-I inhibitor ADC. Gilead also acquired TUB-030, a 5T4-targeted ADC, which has initial clinical data across various solid tumor types.  

Gilead acquired all the outstanding equity of Tubulis for $3.15 billion in upfront considerations on a cash-free, debt-free basis, and up to $1.85 billion in contingent milestone payments. The Tubulis team will continue to be based in Munich, Germany, establishing the Tubulis ADC Innovation Center, which will be a hub for  integrated discovery, manufacturing, and clinical capabilities for ADCs. 

Source: Gilead Sciences